tradingkey.logo
tradingkey.logo
Suchen

Fulgent Genetics Inc

FLGT
Zur Watchlist hinzufügen
20.850USD
+0.030+0.14%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
601.54MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Fulgent Genetics Inc Unternehmen

Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.

Fulgent Genetics Inc Informationen

BörsenkürzelFLGT
Name des UnternehmensFulgent Genetics Inc
IPO-datumSep 28, 2016
CEOHsieh (Ming)
Anzahl der mitarbeiter1313
WertpapierartOrdinary Share
GeschäftsjahresendeSep 28
Addresse4399 Santa Anita Ave
StadtEL MONTE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl91731
Telefon16263500537
Websitehttps://www.fulgentgenetics.com/
BörsenkürzelFLGT
IPO-datumSep 28, 2016
CEOHsieh (Ming)

Führungskräfte von Fulgent Genetics Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Ming Hsieh
Mr. Ming Hsieh
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.87M
-0.05%
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Chief Scientific Officer, Laboratory Director
Chief Scientific Officer, Laboratory Director
926.77K
-0.18%
Mr. Paul Kim, CPA
Mr. Paul Kim, CPA
Chief Financial Officer
Chief Financial Officer
286.01K
-0.73%
Mr. Jian (James) Xie
Mr. Jian (James) Xie
President, Chief Operating Officer
President, Chief Operating Officer
282.94K
-0.76%
Ms. Regina E. (Reggie) Groves
Ms. Regina E. (Reggie) Groves
Independent Director
Independent Director
18.61K
+59.73%
Dr. Michael Nohaile, Ph.D.
Dr. Michael Nohaile, Ph.D.
Independent Director
Independent Director
16.33K
+34.04%
Ms. Linda Marsh
Ms. Linda Marsh
Independent Director
Independent Director
15.54K
-16.55%
Ms. Melanie Solomon
Ms. Melanie Solomon
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Ming Hsieh
Mr. Ming Hsieh
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.87M
-0.05%
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Chief Scientific Officer, Laboratory Director
Chief Scientific Officer, Laboratory Director
926.77K
-0.18%
Mr. Paul Kim, CPA
Mr. Paul Kim, CPA
Chief Financial Officer
Chief Financial Officer
286.01K
-0.73%
Mr. Jian (James) Xie
Mr. Jian (James) Xie
President, Chief Operating Officer
President, Chief Operating Officer
282.94K
-0.76%
Ms. Regina E. (Reggie) Groves
Ms. Regina E. (Reggie) Groves
Independent Director
Independent Director
18.61K
+59.73%
Dr. Michael Nohaile, Ph.D.
Dr. Michael Nohaile, Ph.D.
Independent Director
Independent Director
16.33K
+34.04%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Fulgent Genetics Inc?

Die fünf größten Anteilseigner von Fulgent Genetics Inc sind: Mr. Ming Hsieh

Wie viele Institutionen halten Anteile an Fulgent Genetics Inc (FLGT)?

Mit Stand vom 2026Q1 halten 430 Institutionen Anteile an Fulgent Genetics Inc, mit einem Gesamtmarktwert von etwa 18.21M, was 64.11% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -1416587.00 gestiegen.

Was ist die größte Einnahmequelle von Fulgent Genetics Inc?

Am 2026Q1 erzielte das Geschäft mit Institutional für Fulgent Genetics Inc den höchsten Umsatz in Höhe von 184.60M, was 57.21% des Gesamtumsatzes entspricht.